🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism

Recruitingn/aAges 18 Years - 80 YearsAllEster Ashraf Faried Beshay
NCT06081881 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

to detect the incidence of CTEPH patients. Primary outcome To predict CETHP in symptomatic patients after pulmonary embolism episode. Secondary outcome: On Echocardiography revealed RV dysfunction which are peak TR Velocity , the RV/LV basal diameter ratio, flattening of the IVS, RV acceleration time and/or midsystolic notching, IVC diameter with decreased inspiratory collapse and RA area.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Any patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1, Exclusion Criteria: Secondary causes for pulmonary hypertension Severe kidney injury(eGFR\>30 mg/dl/1.7m2) Hepatic affection Contraindication to anti-coagulation
💊

What it tests

  • Not listed
📍

Where

1 site
Assiut University
Asyut, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy